Facebook Pixel

Meningitis Vaccine Given Accelerated Approval by FDA

Rate This

Accelerated approval for Hiberix, a Haemophilus b Conjugate Vaccine, has been granted by the U.S. Food and Drug Administration, drug maker GlaxoSmithKline said Wednesday.

Hiberix was approved as a booster dose for use in children ages 15 months to 4 years old in order to protect them from invasive disease caused by Haemophilus influenzae type b (Hib), RTTNews reported.

Hib disease is an often serious and potentially deadly bacterial infection that can cause meningitis.

The FDA's accelerated approval is meant to help deal with a shortage in the United States of a vaccine to protect infants from Hib. GlaxoSmithKline said the vaccine should be available within several weeks, RTTNews reported.

Add a CommentComments

There are no comments yet. Be the first one and get the conversation started!

Enter the characters shown in the image.
By submitting this form, you agree to EmpowHER's terms of service and privacy policy


Get Email Updates

Health Newsletter

Receive the latest and greatest in women's health and wellness from EmpowHER - for free!